Genomic Health Launches Oncotype Liquid Biopsy Test
Genomic Health has introduced the Oncotype SEQ Liquid Select, its first liquid biopsy test, the Redwood City, Calif.-based company announced Tuesday.
The next-generation sequencing-based assay assesses 17 genes to identify genomic markers linked to sensitivity or resistance to some FDA-approved therapies to improve treatment selection.
"This blood-based test will provide oncologists with important genomic information reported in a manner that will allow efficient interpretation and identification of potential treatment options,” said Phil Febbo, Genomic Health’s chief medical officer. — Anisa Jibrell